Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12994086 | 1.00 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BCNR1 | |
| SCHEMBL21787346 | 0.96 | CNR2 (0.36) | CNR2HTR2AHTR2CHTR2BCNR1 | |
| SCHEMBL12444491 | 0.91 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BCNR1 | |
| SCHEMBL3272261 | 0.91 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BCNR1 | |
| SCHEMBL12994101 | 0.91 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BCNR1 | |
| SCHEMBL3269907 | 0.91 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BCNR1 | |
| SCHEMBL12994088 | 0.91 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BCNR1 | |
| SCHEMBL15316550 | 0.91 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BCNR1 | |
| SCHEMBL3268569 | 0.91 | CNR2 (0.34) | CNR2HTR2AHTR2CHTR2BCNR1 | |
| SCHEMBL12740619 | 0.90 | CNR2 (0.37) | CNR2HTR2AHTR2CHTR2BCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2199270-B1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-8580142-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20100328600-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2199270-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2010-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100328600-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, MARK3, CCND3 | CNR2 1726/4885HTR2A 2123/4885HTR2C 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.